New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available nationwide
IRVING, Texas – September 8, 2026 – Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading TechBio company, today announced the launch of its new national campaign titled, “Math,” featuring the iconic, award-winning actor, producer and director, Kevin Costner. The partnership is designed to raise awareness of the critical importance of early cancer detection and introduce a national audience to Caris Detect™, Caris’ groundbreaking multi-cancer early detection (MCED) blood test.
At the heart of the “Math” campaign is a simple but powerful promise: when cancer is found earlier, patients may have more treatment options and better outcomes. Caris Detect is designed to help individuals gain earlier insight into their health through advanced blood-based testing powered by molecular science and artificial intelligence. By providing information that may help identify cancer-associated signals before symptoms appear, Caris Detect empowers people to take a more proactive role in their healthcare.
Caris Detect is a multi-cancer early detection blood test designed to identify cancer-associated molecular signals in the bloodstream. The test combines ultra-deep Whole Genome Sequencing (WGS), Whole Transcriptome Sequencing (WTS), and advanced artificial intelligence to analyze a broad range of biological signals associated with cancer. Caris Detect analyzes the entire genome and transcriptome to provide a more comprehensive view of molecular patterns associated with cancer compared to approaches that evaluate only a limited subset of biomarkers.
“Early detection remains one of the greatest opportunities to save lives-,” said David Dean Halbert, Founder, Chairman and Chief Executive Officer of Caris Life Sciences. “With Caris Detect, we are applying decades of leadership in molecular science and artificial intelligence to help create a future where cancer may be detected earlier, when treatment options are broader and survival rates are improved. Kevin’s authenticity, credibility, and ability to connect with people across generations will inspire more people to take a proactive approach to their health.”
Costner partnered with Caris because of the company’s mission to transform healthcare through earlier detection and advanced molecular science. The campaign highlights a simple belief: when people have access to better information earlier, they can make more informed healthcare decisions.
“Cancer has touched so many families, including people I know and care about,” said Kevin Costner, award-winning actor, director and producer. “What attracted me to a partnership with Caris was their commitment to helping people get information earlier and its belief that science and technology can help change what’s possible. If a conversation about early detection encourages even one person to become more proactive about their health, that’s meaningful. Get the test.”
Individuals interested in learning more about Caris Detect may visit CarisDetect.com.
About Caris Detect™
Caris Detect™ is a multi-cancer early detection blood test designed to identify cancer-associated molecular signals using ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and advanced artificial intelligence. The test analyzes a broad range of molecular information to help support earlier detection and more informed healthcare conversations. Caris Detect is designed to complement routine cancer screening and is now available nationwide.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading TechBio company actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
Forward Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “potential,” “contemplate,” “believe,” “estimate,” “predict,” or “continue” or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; continued development, performance and commercialization of Caris Detect; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.